Victoria Biomedical Research Institute

What Victoria Biomedical Research Institute does

Victoria Biomedical Research Institute (VIBRI) is a Kenya-based non-profit biomedical research organization headquartered in Kisumu, operating a network of clinical research sites across Kenya (Kisumu, Rachuonyo County Referral Hospital, Butere County Referral Hospital) with consortium partner sites in the Democratic Republic of Congo (University of Kinshasa) and Rwanda (Rinda Ubuzima). The institute focuses on clinical trials, vaccines, and pharmacovigilance research, executing Phase I-IV trials including adaptive trial designs, bioequivalence studies, epidemiology and population health research, implementation science, and data science and statistics, with therapeutic coverage spanning communicable diseases (malaria, HIV/AIDS, tuberculosis, RSV, Yellow Fever, COVID-19), non-communicable diseases (sickle cell, diabetes, cardiovascular, asthma, oncology, maternal health), and diagnostic and medical device validation. VIBRI also maintains a Cancer Biology Research Group, an Institutional Review Board (VIBRI IRB), and a Community Advisory Board (CAB) to support ethical and community-grounded trial execution.

The organization is led by Founder and Board Chairman Dr. Lucas Tina and CEO Dr. Diana Odhiambo, with a full C-suite (COO David Ogolla, CFO Fredrick Muyela, CAO Josephine Akinyi), Board Members including Dr. Amos Ndhere, Board Advisor Dr. Cheryl Keech, and department leads across laboratory, data, field, regulatory, procurement, and legal functions; headcount sits in the 51-100 range. VIBRI's product platform is built around six interconnected service lines (Clinical Trials & Adaptive Trial Design, Bioequivalence Studies, Epidemiology & Population Health, Implementation Science and Programs, Data Science and Statistics, Training and Capacity Building) supported by an in-house site network, IRB, and CAB.

VIBRI operates a hybrid donor-grant and contract research revenue model: the most prominent funding event is a CEPI grant of up to US$12.5 million (announced June 2022) for a multi-country COVID-19 vaccine booster trial in adolescents and adults living with HIV, complemented by contract research services sold to pharmaceutical companies, global health agencies, governments, and academic and non-profit organizations via a direct B2B/B2G enterprise sales motion. The organization holds official research institution registration from Kenya's National Commission for Science, Technology, and Innovation (NACOSTI, certificate NACOSTI/2025/09/036, granted September 9, 2025) and leads the VIBRI Africa Consortium of academic and research partners across East and Central Africa.

Name

Victoria Biomedical Research Institute

Legal name

Victoria Biomedical Research Institute

Website

https://vibriafrica.org

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

51–100 employees

Short description

VIBRI is a Kenya-based non-profit biomedical research institute operating a multi-country network of clinical research sites across Kenya, DRC, and Rwanda, running Phase I-IV clinical trials, vaccine, bioequivalence, and population health studies for pharmaceutical, global health, academic, and non-profit clients.

Ownership category

akta.pro rank

Product category

Contract Clinical Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Medical and Diagnostic Laboratories (6215)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734), Services-Medical Laboratories (8071)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industry

Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines) (HLACAOAO)

Keywords

• Clinical trial services
• Vaccine research
• Bioequivalence studies
• Epidemiology research
• Contract research organization

Headquarters

HQ city

Kisumu

HQ country

Kenya

HQ region

Africa

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Donor-Funded Research Grants: VIBRI operates as a non-profit organization primarily funded through donor investments from organizations like CEPI (Coalition for Epidemic Preparedness Innovations), which provided up to US$12.5 million for COVID-19 vaccine booster research. Research is conducted in partnership with pharmaceutical companies, governments, and global health agencies.
2. Contract Research Services: Providing pharmaceutical, academic research, and non-profit organizations with clinical trial services, bioequivalence studies, and regulatory-compliant research across the network of clinical sites in Africa.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Victoria Biomedical Research Institute (VIBRI) is a Kenya-based non-profit contract research organization that designs and conducts clinical trials (Phase I–IV, including adaptive designs) for pharmaceutical companies, global health agencies, governments, and academic institutions. It delivers bioequivalence studies, epidemiology and population health research, implementation science, data science and statistics, and training services through a network of clinical research sites across Kenya, the Democratic Republic of Congo, and Rwanda.

Product overview

Victoria Biomedical Research Institute (VIBRI) operates as a non-profit research organization offering a comprehensive suite of clinical research services. The core offerings include six interconnected thematic areas: Clinical Trials & Adaptive Trial Design, Bioequivalence Studies, Epidemiology & Population Health, Implementation Science and Programs, Data Science and Statistics, and Training and Capacity Building. These services are supported by specialized research programs in Cancer Biology Research Group, Communicable Diseases Research, and Non-Communicable Diseases Research. The organization also provides community engagement services through its Community Advisory Board (CAB) and maintains ethical oversight via its VIBRI IRB. VIBRI operates a network of clinical research sites across Africa to facilitate clinical trial execution.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trials & Adaptive Trial Design Design and implementation of ethically robust, internationally compliant Phase I-IV clinical trials including vaccine and therapeutic efficacy studies, adaptive trial designs, and safety monitoring for pharmaceutical sponsors, global health agencies, and academic partners.
• Bioequivalence Studies Comparative bioavailability and bioequivalence studies including pharmacokinetic and statistical analysis aligned with global regulatory standards, supporting generic medicine approvals for pharmaceutical sponsors.
• Epidemiology & Population Health Population-level health research generating evidence on disease patterns, risk factors, and health system performance to support data-driven decision-making for governments and global health agencies.
• Implementation Science and Programs Program design, optimization, and scale-up research ensuring evidence-based health interventions achieve real-world impact in complex African health systems, delivered for non-profits, donors, and public sector clients.
• Data Science and Statistics Statistical research, data systems infrastructure, predictive analytics, forecasting, and data visualization services providing the analytical backbone for clinical trials, epidemiological studies, and policy decisions.
• Training and Capacity Building Professional training, institutional capacity strengthening, mentorship, and knowledge transfer programs building resilient and self-sustaining African clinical research institutions.
• Clinical Research Sites Network Network of clinical research sites across Africa (Kenya, Democratic Republic of Congo, Rwanda) including VIBRI Kisumu, Rachuonyo County Referral Hospital, and Butere County Referral Hospital, providing site infrastructure for multi-country clinical trials.

Quantifiable outcome

• Faster regulatory and ethical approvals, start-up, and recruitment timelines
• +2 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• VIBRI Africa Consortium (University of Kinshasa, Rinda Ubuzima-Rwanda, ACE Research)coreStrategic or Co-development Partner · 1 March 2023VIBRI leads a consortium including University of Kinshasa (DRC), Rinda Ubuzima-Rwanda, and ACE Research for conducting multi-country clinical trials. The consortium enables cross-border research collaboration and leverages diverse expertise and patient populations across East and Central Africa.
• NACOSTI (National Commission for Science, Technology, and Innovation)coreOthersKenya's regulatory body that officially registered VIBRI as a research institution under certificate NACOSTI/2025/09/036, granting formal recognition for conducting biomedical research in Kenya.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Syneos Health: Global biopharma solutions organization running full-service clinical trials across all phases, including in emerging markets. Comparable end-to-end clinical trial execution model and adaptive trial capabilities.
• IQVIA: Largest global CRO offering Phase I-IV clinical trial operations across 100+ countries, including Africa. Comparable in clinical trial execution, biostatistics, and adaptive design capability, though IQVIA serves a much broader sponsor base and geography than VIBRI.
• Parexel: Major global CRO with deep vaccine, infectious disease, and biopharma trial expertise. Comparable in late-phase vaccine and therapeutic trial execution, with broader geographic coverage and larger sponsor portfolio than VIBRI.
• ICON plc: Global CRO providing full-service clinical research, bioequivalence, and laboratory services across multiple therapeutic areas. Comparable to VIBRI's clinical trials and bioequivalence offerings at a much larger scale and global sponsor reach.
• Charles River Laboratories: Global CRO offering preclinical and clinical research services, including bioequivalence and Phase I trials. Comparable in bioequivalence and early-phase trial design, though Charles River operates at global scale with significantly larger capacity.
• European & Developing Countries Clinical Trials Partnership (EDCTP): Public-public partnership funding clinical trials in sub-Saharan Africa for HIV, TB, malaria, and emerging infections. Comparable target disease areas and funder relationships, but operates as a funder rather than executing CRO.

Direct peers

• Ifakara Health Institute: Tanzanian health research organization running malaria, TB, and vaccine trials. Comparable as an African non-profit research institute executing multi-disease clinical research with international funder backing.
• Kenya Medical Research Institute (KEMRI): Kenyan government-affiliated biomedical research institute conducting clinical trials in infectious and non-communicable diseases. Closest domestic peer — overlapping therapeutic focus areas (malaria, HIV, TB), government recognition, and African patient population access.
• MRC/UVRI Uganda Research Unit on AIDS: East African clinical research unit focused on HIV, vaccines, and emerging infections with multi-decade investigator experience. Closely comparable on vaccine trial execution, investigator pedigree, and African population research footprint.

Regional players

• Drugs for Neglected Diseases initiative (DNDi): Non-profit R&D organization developing treatments for neglected diseases in Africa and other low-resource settings. Comparable non-profit model, donor-funded structure, and focus on diseases prevalent in African populations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/victoriabiomedicalresearchcinstitute

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Victoria Biomedical Research Institute